Carboplatin + Topotecan Interaction
Majorinteraction on record
Description
Combination causes greater myelosuppression than topotecan alone with sequence-dependent interaction. Dose reduction of both agents required, particularly when coadministered on day 1 versus day 5 of topotecan dosing.
Mechanism
Myelosuppression; sequence-dependent interaction affecting severity based on administration timing
Source: NLP:topotecan